Latest Distribution Agreements News

Memphasys Limited is intensifying its commercial push for Felix, an innovative automated sperm separation system for IVF, backed by a landmark Middle East partnership and a fresh capital raise to scale manufacturing and sales.

RooLife Group has secured a $64 million two-year supply agreement to distribute its branded coffee and food products in China, reinforcing its expansion strategy in the fast-growing market.

Memphasys has upgraded its contract with ITL to A$390,000 and expanded its territory to include Turkey, marking its first contracted revenues in the EU ahead of expected CE Mark approval.

Memphasys has inked a five-year exclusive distribution agreement with Middle East leader ITL, unlocking a $325,000 initial order for its Felix™ fertility system upon CE Mark approval. This deal opens access to 15 countries and over 350 IVF clinics, setting the stage for rapid regional adoption.

Merino & Co. has secured a strategic offtake and distribution agreement with Chinese apparel giant BINJORA, marking a significant step into the Chinese market with an initial order exceeding $50,000. The partnership also includes co-branded product development for Australia, leveraging BINJORA’s manufacturing strengths.

RooLife Group Ltd reported a sharp 51% revenue decline to $4.62 million and a 31% increase in net loss to $2.76 million for FY2025, as it pivots towards higher-margin sectors including renewable energy and global social commerce.

TasFoods reports a $3.6 million net loss for H1 2025, impacted by oversupply and discounted poultry prices, while advancing key initiatives including pet treats expansion and planned divestments.

Osteopore Limited reported a 6% increase in revenue to $1.56 million for the half-year ended June 2025, alongside a slight rise in net loss driven by expanded product development and compliance costs. The company secured key regulatory approvals and broadened its distribution footprint in Asia and the US.

Aumake Limited reported a strong 54% jump in revenue to nearly $40 million for FY25, while cutting its net loss by 45%. The company’s strategic pivot to higher-margin products and key distribution deals set the stage for an ambitious FY26.

Spectur Limited reported a 6% revenue increase to $8.7 million and slashed its net loss by 70% to $779,000 in FY25, driven by operational restructuring and a shift toward recurring revenue streams.

Firebrick Pharma reported a substantial increase in Nasodine Nasal Spray revenues in FY25, alongside a widening net loss driven by reduced R&D incentives and increased marketing investments. The company is advancing its international rollout with new licensing deals and board appointments.

OncoSil Medical reported a $15.1 million loss for FY25 amid strong revenue growth and significant regulatory milestones, supported by over $14 million in capital raises to fuel its global expansion.